首页> 外文期刊>Lupus >Remission of proteinuria indicates good prognosis in patients with diffuse proliferative lupus nephritis
【24h】

Remission of proteinuria indicates good prognosis in patients with diffuse proliferative lupus nephritis

机译:蛋白尿缓解表明弥漫性增生性狼疮肾炎患者预后良好

获取原文
获取原文并翻译 | 示例
           

摘要

Proteinuria is a well-known risk factor for the progression of renal dysfunction in chronic kidney disease; however, its importance for estimating the prognosis of lupus nephritis requires verification. Korean adult patients with renal biopsy-diagnosed diffuse proliferative lupus nephritis who had undergone three or more consecutive urine protein to creatinine ratio or urine dipstick tests within six months after renal biopsy were enrolled. The cumulative risks, predictors, and outcomes of proteinuric remission and flare were evaluated. This study included 26 men and 167 women with a mean age at renal biopsy of 31.2 +/- 9.8 years. Eighty-two (42.5%) patients experienced proteinuric remission during the follow-up period. During a mean follow-up of 157.9 +/- 69.5 months, among patients who achieved proteinuric remission, one died, one developed end-stage renal disease (ESRD), and two had composite outcomes; among patients without remission, nine died, 24 developed ESRD, and 30 had composite outcomes. Patients who achieved proteinuric remission had a 0.089-fold risk (95% CI: 0.011-0.736) of mortality, 0.110-fold risk (95% CI: 0.013-0.904) of incident ESRD, and 0.210-fold risk (95% CI: 0.048-0.920) of a composite outcome compared to patients without remission. Among the 82 patients who achieved proteinuric remission, 59 (72.0%) experienced at least one proteinuria flare; however, relapse did not correlate with the incidence of outcomes. In conclusion, proteinuric remission is an independent predictive prognostic marker of good renal survival and mortality, regardless of the interval from biopsy to remission, recurrence of proteinuria after remission, renal function status at remission, or hematuria remission.
机译:蛋白尿是慢性肾脏病中肾功能不全的众所周知的危险因素。然而,其对于评估狼疮性肾炎预后的重要性需要进行验证。入选了经肾脏活检诊断为弥漫性增生性狼疮肾炎的韩国成年患者,他们在肾脏活检后六个月内接受了连续三个或三个以上尿蛋白/肌酐比值或尿量尺检查。评估了蛋白尿释放和耀斑的累积风险,预测因素和结果。这项研究包括26位男性和167位女性,平均肾脏活检年龄为31.2 +/- 9.8岁。八十二(42.5%)例患者在随访期间出现蛋白尿缓解。在平均157.9 +/- 69.5个月的随访中,获得蛋白尿缓解的患者中有1例死亡,1例发展为终末期肾脏疾病(ESRD),2例具有复合预后。在无缓解的患者中,有9例死亡,24例发展为ESRD,30例具有复合结果。达到蛋白尿缓解的患者死亡风险为0.089倍(95%CI:0.011-0.736),发生ESR​​D的风险为0.110倍(95%CI:0.013-0.904),风险为0.210倍(95%CI: (0.048-0.920)与没有缓解的患者相比。在获得蛋白尿缓解的82位患者中,有59位(72.0%)经历了至少一次蛋白尿发作。但是,复发与结局的发生率无关。总之,蛋白尿缓解是良好的肾脏生存和死亡率的独立预测预后标志物,无论从活检到缓解,缓解后蛋白尿复发,缓解时肾功能状态或血尿缓解的间隔时间如何。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号